Today: 3 June 2026
Browse Category

Pharmaceuticals 10 February 2026 - 19 February 2026

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK shares fell 0.4% in early London trading Thursday after the company released new real-world data on its RSV vaccine Arexvy and the stock went ex-dividend. A U.S. study linked Arexvy to reduced RSV-related hospitalisations and lower rates of major cardiovascular events in adults over 60. GSK also bought back 420,000 shares on Feb. 17. Investors await further RSV data and updates on dividends.
19 February 2026
····
Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

CSL shares closed up 0.95% at A$154.19 in Sydney, marking a second consecutive gain after announcing a US$100 million licensing deal with Eli Lilly for clazakizumab. ASX filings showed CSL continued its share buyback and a director increased holdings. The stock remains about 15% below early-February levels. CEO Paul McKenzie is set to retire, with Gordon Naylor named interim chief.
19 February 2026
···
Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

GSK shares rose 1.1% to 2,263 pence after the European Commission approved its twice-yearly asthma drug Exdensur and the company launched a new tranche of share buybacks. GSK will repurchase up to £0.45 billion in shares by April 24. The company also reported new real-world data showing its RSV vaccine Arexvy was 75.6% effective against RSV-related hospitalisation in adults over 60.
18 February 2026
··
Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly reported its cancer drug Retevmo beat placebo on event-free survival in a Phase 3 trial for early-stage RET fusion-positive non-small cell lung cancer. U.S. markets are closed for Presidents Day, delaying any stock reaction until Tuesday. Lilly shares last closed at $1,040, up 0.2% Friday. Full trial data will be presented at a future medical meeting.
16 February 2026
··
AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie shares closed up 1.8% at $231.50 Friday, outpacing Johnson & Johnson. U.S. markets will be closed Monday for Presidents Day, with trading set to resume Tuesday. Investors are weighing AbbVie’s drug-pricing moves and pipeline as the company shifts away from Humira after patent loss. Trading volume topped its recent average, with the stock about 5% below its 52-week high.
15 February 2026
··
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
15 February 2026
··
Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex shares jumped 5.7% to $491.47 Friday after Oppenheimer upgraded the stock, citing growth plans beyond cystic fibrosis. The company set 2026 revenue guidance at up to $13.1 billion, with at least $500 million expected from new products. Vertex highlighted gene-editing, pain, and kidney therapies in its outlook. U.S. markets close Monday for Presidents Day.
14 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck shares climbed 1.8% to $121.41 in after-hours trading Friday after Deutsche Bank upgraded the stock and raised its price target. The move comes ahead of key cancer study results set for release at the ASCO Genitourinary Cancers Symposium later this month. Merck’s chief marketing officer sold 10,000 shares on Feb. 12. U.S. markets are closed Monday for Washington’s Birthday; trading resumes Tuesday.
13 February 2026
··
Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly shares rose 0.6% to $1,044.62 after the company disclosed $1.5 billion in pre-launch inventory for its experimental obesity pill, orforglipron, ahead of an expected FDA decision in April. The company also repurchased $4.1 billion in shares in 2025 and raised its quarterly dividend. Chinese regulators approved Lilly’s mirikizumab for Crohn’s disease and ulcerative colitis. U.S. stocks slipped in midday trading.
13 February 2026
··
Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly shares rose 1.8% to $1,033.23 in late morning New York trade after Chinese regulators approved mirikizumab for Crohn’s disease and ulcerative colitis. Investors are watching a Feb. 13 ex-dividend date and an expected U.S. decision in April on Lilly’s oral weight-loss pill. Novo Nordisk shares slipped as it announced plans to launch Wegovy in vials.
12 February 2026
··
Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer shares slipped 0.3% to $27.52 in premarket trading Wednesday after a 2.1% gain the previous session. The company agreed to a $29 million settlement with the SEC over a 2013 insider-trading case tied to SAC Capital, pending court approval. Pfizer joined Swiss biotech incubator BaseLaunch as a partner. Investors await Friday’s U.S. consumer price index report.
11 February 2026
···
AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie shares rose 0.7% to $224.83 Tuesday afternoon, near the session high, after BNP Paribas Exane raised its price target to $213 but kept a neutral rating. The stock traded in a narrow range as investors awaited delayed U.S. payrolls and inflation data for rate signals. U.S. stocks were mixed, with the Dow at a record high and S&P 500 little changed.
10 February 2026
··
1 … 3 4 5 6 7 … 41

Latest articles

Amazon Gets June Prime Day Announcement, Stock Falls

Amazon Gets June Prime Day Announcement, Stock Falls

3 June 2026
Amazon shares slid 1.81% to $256.52 even as it set June 23-26 for Prime Day, giving investors an early look at retail momentum before Q2 ends; despite strong AWS growth and rising net sales, free cash flow fell as AI investments surged, leaving investors cautious about whether Prime Day’s grocery push and earlier timing will boost margins or just shift demand.
Apple Shares Reach New High as AI Decision Looms

Apple Shares Reach New High as AI Decision Looms

3 June 2026
Apple surged 2.9% to a record $315.20, adding $598 billion in May, as investors bet next week’s WWDC will reveal major AI advances; with high expectations and a $100 billion buyback, the stock’s rally leaves little room for disappointment on Siri upgrades, AI features, or rising memory-chip costs.
GameStop Reports Record Profit, Plans $2 Billion Buyback as eBay Concerns Surface

GameStop Reports Record Profit, Plans $2 Billion Buyback as eBay Concerns Surface

3 June 2026
GameStop posted record Q1 net income of $389.6 million, fueled by collectibles now making up 41.8% of sales, and unveiled a new $2 billion share buyback; shares jumped 7.4% in after-hours trading as investors reacted to the earnings beat and capital return plan, even as the company warned future results hinge on collectibles demand and market risks.
Ulta Beauty Raises Outlook, Shares Jump on Steady Beauty Demand

Ulta Beauty Raises Outlook, Shares Jump on Steady Beauty Demand

2 June 2026
Ulta Beauty shares jumped 7% in extended trading after quarterly earnings and comparable sales beat estimates, prompting the company to raise its full-year profit forecast as shoppers spent more on higher-priced beauty products; net income climbed to $340.5 million and gross margin improved to 40.1%, though Ulta warned inflation and macro pressures could impact future spending.
GitLab shares rise on stronger AI outlook, 350 layoffs announced

GitLab shares rise on stronger AI outlook, 350 layoffs announced

2 June 2026
GitLab shares jumped 7% in late trading after beating Wall Street sales estimates and raising its annual forecast, as investors weigh whether its AI-powered Duo Agent Platform can boost growth amid a 14% workforce cut and continued competition from Microsoft’s GitHub.
Go toTop